Overview

FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-03-01

Target enrollment:

Participant gender:

Summary

This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.

Phase:

PHASE1

Details

Lead Sponsor:

Medical College of Wisconsin

Treatments:

daratumumab